2 results about "Proteus mirabilis" patented technology

Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron-emitting mannitol analogue, [18F]fluoromannitol ([18F]FMtl), are rapidly taken up by gram-positive and gram-negative bacteria such as E. coli, S. aureus, A. baumannii, S. epidermis, P. mirabilis, S. enterica, K. pneumonia, E. faecium, E. cloacae, and M. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.

This invention discloses primers and a detection method for triple PCR detection of *Morganella morganii*, *Proteus vulgaris*, and *Providencera reticularis*. The primers are Mm-F, Mm-R, ureC-F, ureC-R, trpD-F, and trpD-R, with nucleotide sequences shown in SEQ ID NO. 1–6. This invention provides a triple PCR detection method for simultaneously detecting *Morganella morganii*, *Proteus vulgaris*, and *Providencera reticularis*. This method is highly specific, sensitive, rapid, and accurate, and can be used for clinical and laboratory PCR detection of *Morganella morganii*, *Proteus vulgaris*, and *Providencera reticularis* in alligator gout. It has broad application potential in rapid pathogen detection and epidemiological investigation of alligator gout.